EAU 2025 | Professor Anders Kjellman: Biopsy Before Treatment Plays a Key Role in Managing Small Renal Masses (SRMs)
Pathological diagnosis is the foundation of effective cancer treatment. It not only helps avoid unnecessary treatment for benign tumors but also supports the development of individualized therapeutic strategies. When small…
CSCO BC | “Best of SGBCC” Resonates at the National Breast Cancer Conference: Bridging Borders, Advancing Science
On April 12, 2025, the “Best of St. Gallen 2025” session, co-hosted by the Breast Cancer Committee of the Chinese Society of Clinical Oncology (CSCO BC) and the St. Gallen International Breast Cancer Conference (SGBCC), was successfully held during the National Breast Cancer Conference in China.
Writing China’s Own Guidelines: Professor Zefei Jiang on the Evolution and Global Vision of the CSCO Breast Cancer Guidelines
As one of the five initial professional guideline projects launched by the Chinese Society of Clinical Oncology (CSCO) in 2016, the CSCO Breast Cancer Guidelines (CSCO BC Guidelines) have become a cornerstone of breast cancer care in China. Since the publication of the first edition in 2017, the guidelines have undergone yearly updates, evolving in both content and format. Today, they are available in multiple versions—including Chinese and English editions, pocket guides, patient education materials, and AI-based platforms—earning broad recognition from Chinese clinicians and international oncology peers alike.
Professor Zhengqiang Yang Offers In-Depth Interpretation of the 2024 Edition of the Primary Liver Cancer Guidelines: Updates in Interventional and Local Therapies
Since the release of the 2022 edition of the Primary Liver Cancer Diagnosis and Treatment Guidelines, numerous high-quality studies—both domestic and international—have advanced the field of hepatocellular carcinoma (HCC), especially in diagnosis, staging, and treatment. Research reflecting China's real-world clinical settings has provided important theoretical guidance for the management of liver cancer. Building on accumulated clinical experience, the National Health Commission has organized expert teams to revise the guidelines, culminating in the publication of the 2024 edition, which introduces comprehensive updates across screening, diagnosis, and treatment.
Professor Zhengqiang Yang on 2024 Liver Cancer Guidelines: Advances in Interventional and Local Therapies
Since the release of the 2022 edition of the Primary Liver Cancer Diagnosis and Treatment Guidelines, numerous high-quality studies—both domestic and international—have advanced the field of hepatocellular carcinoma (HCC), especially…
CSCO BC Guidelines | Unlocking a New Chapter in Anti-HER2 Therapy — Professor Jianbin Li Interprets Key Updates to the 2025 CSCO BC Guidelines
The 2025 National Breast Cancer Conference was held in Beijing from April 11 to 13, during which the newly updated 2025 edition of the CSCO Breast Cancer Guidelines (CSCO BC…
Cancer Patients Rehabilitation Rally is Underway!
On April 20, 2025, the "Beyond Limits" Cancer Patients Rehabilitation Rally was officially launched across China. Organized by the Cancer Rehabilitation Society of CACA , and supported by Hengrui Pharmaceuticals, the initiative harnesses digitization and other cutting-edge technologies to enhance long-term survival rates and quality of life for cancer patients.
Professor Ziyu Li: JGCA China-Japan Joint Session Opens with a Spotlight on Function-Preserving Surgery for Gastric Cancer
Since 2016, the Gastric Cancer Committee has actively promoted China-Japan academic exchange by establishing a dedicated Chinese session at the JGCA annual meeting. In 2019, under the initiative and support…
IGCC 2025 | Professor Zekuan Xu to Present on China’s Current Clinical Research Landscape in Gastric Cancer
The 16th International Gastric Cancer Congress (IGCC 2025), hosted by the International Gastric Cancer Association, will take place from May 7–10, 2025, in Amsterdam, the Netherlands. The Oncology Frontier will…